Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Amylyx(AMLX) Businesswire·2024-03-08 20:00Amylyx(AMLX) Businesswire·2024-03-08 20:00
R1Amylyx(AMLX) Businesswire·2024-03-08 20:00 R1Amylyx(AMLX) Businesswire·2024-03-08 20:00